Moderna's Investigational Therapeutic mRNA-3705 in FDA's START Pilot Program

Thursday, 6 June 2024, 08:28
The U.S. Food & Drug Administration has selected Moderna's investigational therapeutic mRNA-3705 for the START Pilot Program. This collaboration signifies a significant milestone for Moderna in advancing treatment options for Methylmalonic Acidemia patients.
https://store.livarava.com/896baa35-23f9-11ef-a40f-9d5fa15a64d8.jpg
Moderna's Investigational Therapeutic mRNA-3705 in FDA's START Pilot Program

Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program

Moderna's investigational therapeutic mRNA-3705 has been chosen by the U.S. Food & Drug Administration to participate in the START Pilot Program. This selection highlights the potential of mRNA-3705 in addressing Methylmalonic Acidemia, a rare genetic disorder.

Do you want to advertise here? Contact us

Related posts

Do you want to advertise here? Contact us
Do you want to advertise here? Contact us
Newsletter

We carefully select news from the world of finance and publish it for our users. We understand the importance of reliable and up-to-date information for people in the financial world. Do you want to receive news in a convenient format and always have it at hand — subscribe to our newsletter and make your analytical work more effective.

Subscribe